• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

EKG, Other Heart Health Features Come to Apple Watch
NEW YORK (AP) — Apple Watch is now fulfilling its promise to let people take EKGs of their heart and notify them of any irregular heartbeat. Apple announced the heart features in September, but didn't make them available until Thursday. The new features have been given clearance by the U.S. Food and Drug Administration and are for U.S. customers only. Related JEMS Article: The iBeat Is a ‘Smart’ Watch, But It Can’t ‘Save Your Life’ The watch can intermittently check the wearer's heart rhythm in the background and send a notification if it detects irregular heart rhythm. That can point to atrial fibrillatio...
Source: JEMS Patient Care - December 7, 2018 Category: Emergency Medicine Authors: Associated Press Tags: Cardiac & Resuscitation News Source Type: news